Corporate Update – Flex Ltd to Showcase New Data at 2026 ESMO Breast Cancer Congress
Flex Ltd announced that it will present new data at the 2026 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. The company plans to showcase two poster presentations that draw on findings from the prospective FLEX Study and an independent post‑hoc analysis of the MINDACT trial.
First Poster: Prognostic Performance of the MammaPrint Assay in Small, Node‑Negative Early‑Stage Breast Cancer
The first poster will focus on the prognostic performance of the company’s MammaPrint assay in patients with small, node‑negative early‑stage breast cancer. The analysis, which included over 4,300 patients, identified a small subset of tumors classified as High‑Risk 2 that demonstrated a poorer recurrence‑free survival compared with those in the Low/Ultra‑Low risk categories.
Key take‑aways for clinicians and IT decision‑makers:
| Parameter | Findings | Clinical Implication |
|---|---|---|
| Patient cohort | 4,300+ small, node‑negative early‑stage breast cancer patients | Broad applicability across common clinical settings |
| Risk stratification | High‑Risk 2 tumors had statistically significant worse outcomes | Even patients with favorable clinical features may benefit from intensified or biologically informed therapy |
| Outcome metric | Recurrence‑free survival (RFS) | RFS can be integrated into electronic health record (EHR) dashboards for real‑time risk stratification |
Expert Perspective Dr. Anil Kumar, an oncologic epidemiologist at the National Cancer Institute, notes that the identification of a high‑risk subgroup within an ostensibly low‑risk population underscores the value of genomic assays in precision oncology. “The data suggest that a one‑size‑fits‑all approach is increasingly untenable,” he said. “Integrating MammaPrint results into clinical decision support systems could help tailor adjuvant therapy regimens, potentially sparing patients from overtreatment.”
Second Poster: Body Mass Index and Distant Recurrence Dynamics in the MINDACT Cohort
The second poster examines the relationship between body mass index (BMI) and distant recurrence dynamics in the MINDACT cohort. The exploratory analysis, led by co‑founder Laura van ‘t Veer, found a non‑linear association:
| BMI Category | Distant‑Metastasis Risk | Time Course | Interpretation |
|---|---|---|---|
| Obesity (≥30) | Lower risk than normal weight | Sustained low risk | Possible protective metabolic effect |
| Normal weight (18.5‑24) | Baseline risk | Stable | Conventional baseline |
| Overweight (24‑28) | Peak risk around 6 years | Declining thereafter | Time‑dependent risk window |
The findings highlight the need for further research to refine time‑dependent treatment strategies based on weight.
Data Points for IT Professionals
- Data Integration: BMI and MammaPrint results can be merged into predictive analytics pipelines to forecast recurrence risk over time.
- Visualization: Dashboards should incorporate time‑dependent risk curves to aid oncologists in scheduling surveillance and treatment adjustments.
- Data Governance: Ensure that BMI data, often self‑reported, are validated against electronic health records to maintain data quality.
Role of Genomic Assays in Personalized Treatment
Both presentations underline the role of Flex’s genomic assays—MammaPrint and BluePrint—in providing biologically relevant insights that can guide personalized treatment decisions for early‑stage breast cancer patients. By integrating assay results with traditional clinical variables, the company aims to support a shift toward data‑driven oncology workflows.
Actionable Takeaways for IT Decision‑Makers
- Evaluate Integration: Assess the feasibility of incorporating MammaPrint and BluePrint data into existing EHR systems and clinical decision support tools.
- Data Analytics: Deploy predictive models that factor in BMI and risk stratification to generate dynamic recurrence risk profiles.
- Compliance: Ensure that data integration complies with GDPR and other regulatory frameworks governing genomic data.
- Training: Provide multidisciplinary training to clinicians and data scientists on interpreting assay outputs within the context of individual patient profiles.
Industry Context
- Market Growth: The global companion diagnostics market is projected to reach USD 22 billion by 2028, driven by the rise of precision oncology.
- Regulatory Momentum: The European Medicines Agency’s (EMA) recent approvals for genomic testing in oncology create a conducive environment for assay adoption.
- Competitive Landscape: Flex Ltd’s focus on early‑stage breast cancer positions it alongside other genomic testing firms such as Agilent’s GARDENIA and 22q DnaSeq.
By presenting these findings at the 2026 ESMO Congress, Flex Ltd aims to reinforce its leadership in genomic diagnostics and to provide actionable insights that can be translated into improved patient outcomes and more efficient healthcare delivery systems.
